share_log

西藏药业(600211.SH):主力产品新活素暂时没有开展海外销售的具体计划

Tibet Rhodiola Pharmaceutical Holding (600211.SH): There is currently no specific plan for overseas sales of their main product, Xinhuosu.

Gelonghui Finance ·  Jul 11 06:36

On July 11th, Gloden Investment Network received inquiries from an investor on the investor Q&A platform regarding Tibet Rhodiola Pharmaceutical Holding (600211.SH), asking: "Does the company's main product have the potential and plan to expand overseas? Are there products with similar efficacy overseas?" The company replied that the main product, Xinhuosu, does not currently have a specific plan for overseas sales, but the product Imdur is sold overseas. Public information shows that Xinhuosu and Nesiritide from abroad are both products used for the treatment of acute decompensated heart failure.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment